Community Research and Development Information Service - CORDIS

Horizon 2020 project information and now also report summaries are available on CORDIS. All H2020 projects can be downloaded from the EU Open Data Portal .

My refinements


Download results of this page


Refine by:

Advanced search

Results 1 - 10 of 28
Order by: Results/page:
12 3 > 
SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease
ID: 754658
Start date: 2018-01-01, End date: 2022-04-30
CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers...
Programme: H2020-EU.3.1.3.
Record Number: 216603
Last updated on: 2018-08-07
Randomized, Comparison Of Risk-Stratified versus Standard Breast Cancer Screening In European Women Aged 40-74
ID: 755394
Start date: 2018-01-01, End date: 2025-12-31
MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe. Indeed current standard mammographic screening, with entry stratified by age alone, has recently been largely questioned. Despite a demonstrated mean 20% reduction in breast...
Programme: H2020-EU.3.1.3.
Record Number: 212694
Last updated on: 2018-01-23
Liquid biopsies and Imaging for improved cancer care
ID: 755333
Start date: 2018-01-01, End date: 2021-12-31
LIMA’s overall objective is to develop and validate technologies and tools to include liquid biopsies in the clinical workflow, aiming at introducing a more precise and dynamic genetic characterization of tumor at the diagnosis and during treatment phases. This will be done...
Programme: H2020-EU.3.1.1.
Record Number: 212693
Last updated on: 2018-01-23
A pivotal phase IIb clinical trial of inhaled alginate oligosaccharide (OligoG) for cystic fibrosis
ID: 755234
Start date: 2018-01-01, End date: 2020-12-31
The objective of the current proposal is to advance the orphan drug OligoG CF-5/20 (OligoG) through a pivotal phase IIb clinical trial, to enable a new and improved therapeutic approach for the orphan disease cystic fibrosis by 2020.The study drug is an alginate...
Programme: H2020-EU.3.1.3.
Record Number: 212691
Last updated on: 2018-01-23
A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma.
ID: 755179
Start date: 2017-12-01, End date: 2020-11-30
"Glioma is a rare brain cancer with one of the highest mortality rates. It is considered an orphan disease due to its low prevalence (less than 0.5 cases per 10,000 inhabitants in the EU) and the lack of plausible therapies. Based on the discovery of the lipid proliferation...
Programme: H2020-EU.3.1.3.
Record Number: 212688
Last updated on: 2018-01-23
A multidisciplinary approach for the stratification of patients with carotid artery disease
ID: 755320
Start date: 2018-01-01, End date: 2022-12-31
Carotid artery disease, the primary trigger of ischaemic cerebrovascular events including stroke, causes major morbidity, mortality and healthcare costs worldwide. Still, treatment is based on criteria established in the 90s that do not take into account the molecular...
Programme: H2020-EU.3.1.1.
Record Number: 212692
Last updated on: 2018-01-23
Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome
ID: 755225
Start date: 2018-01-01, End date: 2022-12-31
Crigler-Najjar syndrome (CN) is a rare recessive disorder caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1(UGT1A1) gene. CN is a life-threatening disease with no cure which constitutes a severe burden for the patients, their families, and the society...
Programme: H2020-EU.3.1.3.
Record Number: 212689
Last updated on: 2018-01-23
Stem-cell based gene therapy for recombination deficient SCID (RECOMB)
ID: 755170
Start date: 2018-01-01, End date: 2022-12-31
Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SCID) have been successfully treated by autologous stem cell based gene therapy. However, for the most common group of SCID, the SCID...
Programme: H2020-EU.3.1.3.
Record Number: 212687
Last updated on: 2018-01-23
Building social and emotional skills to BOOST mental health resilience in children and young people in Europe
ID: 755175
Start date: 2018-01-01, End date: 2021-12-31
It is widely documented that social and emotional learning (SEL) programs are effective in promoting mental health and well-being in children and young people. However, a number of shortcomings of these programs have been identified, which may compromise their sustainability...
Programme: H2020-EU.3.1.2.
Record Number: 212686
Last updated on: 2018-01-23
Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)
ID: 755094
Start date: 2018-01-01, End date: 2021-12-31
TUDCA-ALS will focus on amyotrophic lateral sclerosis (ALS) a rare neurodegenerative disorder, that affects motor neurons in the brain, brainstem and spinal cord, resulting in progressive weakness and atrophy of voluntary skeletal muscles. ALS has an estimated prevalence of...
Programme: H2020-EU.3.1.3.
Record Number: 212685
Last updated on: 2018-01-23
12 3 > 
List retrieved on: 2018-10-18
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top